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Biotechnology applied to 
the development of vaccines
Mariana de Oliveira diniz 
and luís CarlOs de sOuza Ferreira
One Of the impacts of the modern biotechnology revolution has been a significant shift in the way we think and develop new vaccines. These changes reflect advances in the discovery of new antigens, adjuvants, 
vectors and delivery systems. While many of the vaccines currently administered 
to children and adults are still the result of methodologies developed in the 
mid-twentieth century, it is expected that the next few years will bring a grow-
ing number of new safer and more effective vaccines generated from genetic 
manipulation techniques and the production of recombinant proteins in heter-
ologous systems. In this brief report, we will discuss some aspects of this change 
in practices and knowledge applied to vaccine development. In particular, we 
will emphasize research into the generation of therapeutic vaccines for tumor 
control, and their application to tumors induced by human papilloma virus.
The history of vaccines and their application in the prevention of infec-
tious diseases spans over 200 years of dedication and hard work. Initiated by 
the brilliance and focused empiricism of physicians and researchers like edward 
Jenner and Louis Pasteur, this area provides a beautiful example of reduction-
ism applied to medical practice. Since the first vaccines based on pathogens 
- whether bacteria or viruses, attenuated or inactivated, very reactive and, in 
some cases, little efficient - vaccine research has moved towards the use of in-
creasingly smaller fractions of these pathogens in the quest to increase safety 
without compromising efficacy. Thus, it is common to classify vaccines into 
three major groups (or generations) according to the strategies or concepts used 
in the preparation of the active principle, the vaccine antigens. first generation 
vaccines are those that include the entire pathogen, but subjected to treatments 
that lead to inactivation or attenuation of microorganisms. Also worth noting in 
this category is the strategy in which non-pathogenic microorganisms derived 
from a different host are used as antigens for vaccines aimed at the control of 
diseases caused by different but genetically-similar pathogens. A good example 
of this approach are smallpox vaccines based on vaccinia virus isolated from bo-
vine cattle and TB vaccine that also uses a bacterium originally obtained from 
bovine cattle, the Mycobacterium bovis (BCG). Other highlights in the group of 
first generation vaccines include vaccines against whooping cough or pertussis 
estudos avançados 24 (70), 201020
(vaccine cell), smallpox, polio, measles, rubella, and adenovirus among others.
The second vaccine generation emerged based on the idea that, for some 
pathogens, protection can be achieved after the induction of antibodies directed 
to a single target, such as a toxin, responsible for the disease symptoms, or sur-
face sugars that allow the host immune system to neutralize and destroy bacteria 
that, otherwise, would spread rapidly before being noticed by our main immune 
defense lines. In this group, the highlights are acellular vaccines that use toxoids 
(toxins inactivated and purified by chemical treatments), purified proteins such 
as the vaccines against tetanus, diphtheria, and hepatitis B and polysaccharides, 
such as thoseintended to control meningococcal meningitis and pneumonia.
finally, the third and newest generation of vaccines is based on an innova-
tive concept that distinguishes it radically from the previous vaccine generation. 
These third generation vaccines use the genetic information of the pathogen 
responsible for encoding antigens relevant for protection. Generally called DnA 
or genetic vaccines, third generation vaccines were discovered empirically in the 
early 1990s in trials initially focused on the search of gene therapies in which 
genes are employed to replace defective genetic information originally present 
in the individual affected by certain genetic defects.
The concept of vaccine stemmed from the observation that animals in-
oculated with plasmids carrying genes expressed in transfected cells, i.e., cells 
in which the injected DnA has managed to penetrate the cytoplasmic and nu-
clear membranes and, subsequently, use the enzymatic transcription machinery 
required for translation of the antigen, which will trigger a series of immune 
responses, such as antibodies, essential to ensure protection against pathogens 
circulating in the bloodstream, cytotoxic cells, with the potential to identify 
and destroy infected cells even in the absence of circulating pathogens, and im-
munological memory, which is critical for a long lasting prophylactic effect. Al-
though the initial perspectives for DnA vaccines was frustrated by the poor im-
munogenicity of several vaccines submitted to clinical trials, the results indicate 
that these vaccines can be excellent tools for the activation of cytotoxic immune 
responses and thereby for the control of intracellularly replication pathogens, 
such as viruses, some bacteria and certain types of cancers.
The advent of modern biotechnology, in particular the spread of genetic 
manipulation techniques, has changed in different ways the research and de-
velopment of vaccines, whether of first, second or third generation vaccines. 
Through gene cloning and mutagenesis strategies we can accurately and more 
safely generate attenuated microorganisms (viruses and bacteria). empirically 
isolated attenuated pathogens, used in first generation vaccines, can revert to 
the virulent state. Since in many cases the nature of the genetic change expe-
rienced by the microorganism during the attenuation process is unknown, the 
possibility of reversion to virulence, although unlikely, is a real. The techniques 
currently available for genetic manipulation enable selection , with relative ease, 
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of attenuated mutants in which genes involved with pathogenicity or primary 
metabolism are inactivated so as not to compromise the viability of the organ-
ism, but rather to make it incapable of causing diseases. However, the high costs 
of clinical trials and the established use of certain vaccine formulations such as 
the polio, measles, yellow fever viruses and the bacterium Mycobacterium tu-
berculosis, among others, reduce the interest of industries and laboratories to 
produce or develop new vaccine formulations (Table 1).
Biotechnology has revolutionized second generation vaccines. In an initial 
phase, these vaccines were restricted to the use of inactivated toxins, such as in 
the tetanus and diphtheria vaccine, and in a second phase, purified polysaccha-
rides. The initial use of purified proteins from viruses or bacteria was limited to 
situations in which it was possible to cultivate and purify specific antigens, such 
as certain bacterial toxins, or obtain them from the serum of infected patients, as 
in the case of the hepatitis B virus. With the improvement of recombinant pro-
tein production techniques by heterologous expression systems, such as those 
based in bacteria, yeasts, insect and mammalian cells, are used as sources for an-
tigens to be incorporated into vaccine formulations. In fact, this area of vaccin-
ology based on the generation of subunit vaccines using recombinant antigens 
currently receives greater interest and attracts much investment due both to 
safety and financial return is, such as illustrated by the  vaccine to control hepa-
titis B and, more recently, the preventive vaccine against infections with human 
papillomavirus (HPV) (Table 1).
DnA vaccines emerged as a result of biotechnological advances in re-
combinant DnA. The genetic information encoding antigens with vaccine ap-
plication is cloned and propagated in Escherichia coli strains, a harmless inhabit-
ant of our intestinal microbiota. The production procedure is relatively simple 
and less costly than that involved in obtaining recombinant proteins. Moreover, 
some features of the immune response modulation mediated by DnA vaccines 
have become a valuable tool in the development of therapeutic formulations. 
Undoubtedly, more than conventional preventive vaccines, DnA vaccines rep-
resented an alternative approach to develop and implement immunotherapies 
which became  possible thanks to the introduction of recombinant DnA tech-
niques in vaccine  research (Table 1).
Vaccines with therapeutic properties
Therapeutic vaccines aim to control chronic infections or degenerative 
diseases affecting the individual to be treated. In this respect, the definition of a 
therapeutic vaccine superimposes with the concept of gene therapy, particularly, 
when one makes use of DnA vaccines or live vectors that ultimately transfer 
new genetic information into the host’s cells. In the case of DnA vaccines the 
administration of the heterologous gene will be responsible for producing the 
protein that ultimately will trigger an immune response capable of reversing the 
established infectious or degenerative process. The goal of any therapeutic vac-
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cine is therefore to reverse situations in which the individual’s immune system 
was not able to activate an immune response with the appropriate intensity or 
quality,  leading to the establishment of an immunological tolerance process. 
Obviously, the relevance of the therapeutic vaccine concept makes sense only 
in cases where more efficient therapeutic options are unavailable. Moreover, for 
a therapeutic vaccine to be successful, there must be evidence that the disease 
and, therefore, the pathogen that caused the disease can be controlled by the 
individual’s immune system, once properly activated, as in the case of chronic 
diseases such as those caused by the human immunodeficiency (HIV), human 
herpes (HSV), hepatitis B (HBV) and human papilloma (HPV) viruses.
Advances in the knowledge of immunity mechanisms have enabled defini-
tion of important parameters for a therapeutic vaccine. In particular, the under-
standing of the importantrole of functional cytotoxic T lymphocytes, as well as 
of other immune system cells with similar functions, has represented an impor-
tant step in the advancement of therapeutic vaccines. By recognizing and de-
stroying cells, either infected or altered in their antigenic composition, CD8+T 
cytotoxic lymphocytes are a formidable barrier against pathogens that evade 
other immune defense mechanisms, such as antibody and complement, once the 
pathogen penetrate and multiply inside the host’s cells.
In recent years, several research groups have been devoted to the search 
for vaccine formulations that can activate, in an efficient and long lasting way, 
CD8+T cytotoxic lymphocytes capable of recognizing and destroying cells ex-
pressing on their surface fragments of antigens derived from viral, bacterial or 
parasite pathogens observed after infection. Similarly, vaccines with anticancer 
properties have been investigated for several decades in the hope of finding 
more effective and less invasive alternatives for the treatment of some types of 
cancer. In some cases, the cancer treatments may become more favorable for a 
therapeutic vaccine approach, like cancers linked to an infectious origin, such as 
tumors associated with infection with HBV and HPV. In both cases, the avail-
ability of vaccines with prophylactic properties aimed at the control of infection 
with viruses makes the issue of viability and relevance of therapeutic vaccines 
more complex and, in certain situations, generates interesting controversy about 
the potential role of prophylactic or therapeutic vaccines in the control of the 
different cancer diseases. In this respect, the recent marketing of prophylactic 
vaccines for HPV infection and the search for alternative vaccines with therapeu-
tic properties against tumors associated with infection by this virus represents an 
example that deserves investigation.
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Table 1 – Main contributions of biotechnology to vaccine development 
Vaccine type Biotechnological strategy Vaccines
Sub-unit vaccines Production of 
recombinant 
proteins in 
heterologous 
systems
Hepatitis B, acellular 
pertussis, HPV
Bivalent attenuated 
pathogens 
Genetic manipulation for 
insertion of genes encoding 
antigens
Dengue fever,* BCG,* 
Salmonella
Typhi,* Adenovirus*
DNA vaccines Immunization 
with recombinant 
plasmids
Melanoma vaccine #
* Vaccines not yet available for use in humans;  # vaccine for use in dogs.
The search for a therapeutic vaccine 
to control tumors associated with HPV infections
Currently, it is well established that the human papilloma virus (HPV) is 
the main etiological agent of cervical cancer, as well as of other cancers such as 
anogenital and head and neck tumors. In relation to cervical cancer, the HPV 
virus is associated with virtually all cases observed. This type of cancer is of high 
epidemiological relevance, as it represents the second leading cause of death by 
cancer among women worldwide, causing approximately 270,000 deaths per 
year, with about 500,000 new cases diagnosed annually (Zur Hausen, 2009).
More than 100 types of HPV have been described and can be classified 
according to their oncogenic potential. Some types of HPV can cause low-grade 
genital warts and benign lesions, and are called low-risk genotypes, among 
which the most common are HPV-6 and HPV-11. HPV types associated with 
the development of cervix tumors are called high risk and the most frequently 
found are HPV-16, HPV-18, HPV-31, HPV-33 and HPV-45. HPV-16 and 
HPV-18 are the types most commonly associated with cervical cancer, totaling 
75 percent of the incidence of cases of this cancer, with HPV-16 being the most 
common in Brazil and in most countries (Bosch et al., 1995). Consequently, 
these two types of HPV, particularly HPV-16, have been used as a model for the 
development of vaccine, either prophylactic against virus infections or therapeu-
tic aiming tumor erradication.
Understanding the molecular biology of the HPV virus is essential for vac-
cine development. HPVs are non-enveloped double-stranded DnA viruses. The 
genome of this virus encodes two late expression proteins, L1 and L2 (“L” from 
late), which form the viral capsid, and six proteins with regulatory functions: e1, 
e2, e4, e5, e6 and e7 (“e” from early). In particular, the e6 and e7 proteins 
of high-risk HPVs act on cell maligninization through binding or inactivation 
of the products of tumor suppressor genes, p53 and pRB, respectively (Dyson, 
1998). Thus, cells infected with high-risk HPVs can develop genomic instability 
and uncontrolled replication that can progress to cancer.
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As cervical cancer is caused by a viral infection, there is a expectation that 
a vaccine capable of generating neutralizing antibodies directed against the viral 
capsid proteins L1 and/or L2 will block the virus entry and, thereby, reduce 
the incidence of cancer in the long term. Two prophylactic vaccines based on 
VLPs (Virus Like Particles) formed by the L1 proteins of HPV-6, -11, -16, and 
18 (Gardasil) or HPV-16 and 18 (Cervarix) are available on the market. These 
vaccines have proven to be extremely efficient at inducing neutralizing antibod-
ies to the virus. It is expected, therefore, that individuals immunized with these 
vaccines will be protected against infection with the virus types used in the vac-
cine preparation and, therefore, will not develop cervical cancer in the future. 
However, because of large natural variability, immunity is specific for the viruses 
used to generate VLPs.
Women who have high-grade lesions and HPV-induced tumors do not 
produce viral particles and therefore would not benefit from the VLP-based 
vaccine strategy. By penetrating the epithelial cell, the virus integrates into the 
cellular genome and stops replicating. The synthesis of L protein is completely 
blocked, but the synthesis of some regulatory proteins, in particular the e6 
and e7 oncoproteins, remains unchanged. These cases require the search for 
vaccines aimed at controlling HPV-induced lesions. These vaccines with thera-
peutic anti-tumor properties should favor the induction of cytotoxic responses, 
so as to lead to the recognition and killing of infected cells. The main targets 
for this type of vaccine are the e6 and e7 proteins, constitutively expressed in 
cervical carcinoma cells.
There are no therapeutic vaccines for HPV-induced tumors available on 
the market, but several formulations are being investigated in animal models 
and some are already in the clinical trial phase. Several approaches have been 
used for the development of a vaccine with these characteristics, such as those 
based on synthetic peptides, purified proteins, viral or bacterial vectors and even 
dendritic cells or tumor cells, among others. In this context, DnA vaccines 
emerge as an interesting strategy for the generation of antigen-specific immune 
responses which, for their ability to induce cytotoxic responses, would act only 
on tumor cells, avoiding such side effects as those observed in current radiation 
and chemotherapy treatments.
Some groups engaged in the research of DnA vaccines for the control of 
HPV-induced tumors are seeking to increase the immunogenicity of vaccine 
formulations. In this context, the use of adjuvants or constructions that express 
hybrid proteins in which HPV oncoproteins are fused to antigens that enhance 
immunogenicity for cytotoxic responses has received special attention. A prom-
ising alternative is represented by DnA vaccines encoding HPV proteins geneti-
cally fused to the herpes simplex virus type I (HSV) glycoprotein (gD). The gD 
protein has a transmembrane region, and thus the HPV-16 oncoproteins fused 
thereto are directed to the membrane of transfected cells, thereby drastically re-
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ducing the risk of interaction with cell cycle proteins and exposing them to the 
immune system in a more efficient way.
Other adjuvant roles assigned to the gD protein have been described and 
are associated with the ability to bind to the HVeM receptor (Herpes Virus 
entry Mediator), belonging to the family of tumor necrosis factor receptors 
(TnfR). Through interaction with this receptor, it was demonstrated that the 
gD protein generates stimulus signals to cells of the immune system by activat-
ing a transcription factor, nf-kB (Cheung et al. 2009). Additionally, the gD 
protein increases the immunogenicity of proteins fused thereto by competing 
with another membrane protein called BTLA (B and T Lymphocyte Attenua-
tor), an inhibitory factor that suppresses the activation of B and T lymphocytes 
by antigen-presenting cells, for the same binding site that the two proteins have 
on another cell receptor called HVeM (Herpes Virus entry Mediator). As a 
final result, cells expressing the gD protein on the surface reduce the inhibitory 
effects of BTLA and promote a more efficient activation of B and T lymphocytes 
(Lasaro et al. 2008).
The use of DnA vaccines encoding HPV-16 oncoproteins genetically 
fused to HSV-1 gD protein has been proposed by our group as a strategy for 
controlling HPV-16-induced tumors (Lasaro et al. 2005). These vaccines have 
been tested in mice for their ability to activate antigen-specific CD8+ T cells and 
prevent the development of tumors after implantation of epithelial cells modi-
fied to express the e6 and e7 proteins of HPV-16, called TC-1 cells. Animals 
immunized with these vaccines showed induction of e7-specific CD8+ cells and 
a 40 percent therapeutic antitumor effect against the development of tumors 
after receiving four doses of the vaccines. In these experiments, tumor cells are 
implanted into the animal, followed by treatment with the DnA vaccine, thus 
characterizing the therapeutic vaccine effect.
The vaccine strategy against HPV-16-induced tumors has been improved 
by the construction of a new DnA vaccine expressing the HPV-16 e5, e6 and 
e7 oncoproteins genetically fused to HSV-1 gD (Diniz et al. 2010). experi-
ments designed for checking the activation of CD8+ T cells specific for HPV-16 
oncoproteins showed that a single dose of the vaccine was sufficient to generate 
significant activation of e6 and e7-specific CD8+ cells (figure 1A). The vaccine 
was able to generate 100 percent protection against tumors in animals that were 
first immunized and subsequently challenged with TC-1 cells. The antitumor 
effect of the vaccine was associated with the involvement of CD8+ T cells, but 
not of CD4+ T cells, in trials in which these cell populations were differentially 
removed with antibodies (figure 1B). Moreover, this vector conferred 70 per-
cent protection in mice challenged with TC-1 cells and subsequently immu-
nized with three doses of the vaccine.
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figure 1 – Activation of e7-specific CD8+ T cell precursor  and preventive protec-
tion against tumors induced by TC-1 cells in mice immunized by par-
enteral route (intramuscular) with the pgD-e7e6e5 vector. (A) Activa-
tion of CD8+ T cell precursors in mice i.m. immunized with one dose 
of the pgD, pe7e6e5 or pgD-e7e6e5 vectors (100 µg / dose). The 
percentages of CD8+ Ifn-γ+ / CD8+ total cells were determined two 
weeks after the last dose of the vaccine. Detection of e7-specific CD8+ T 
cells was performed with PBMC stimulated with synthetic peptide derived 
from e7 protein (49RAHYnIVTf57) specific for MHC-I and stained 
with anti-CD8 (fITC) and intracellular Ifn-γ antibodies (Pe). (B) Vac-
cine induced preventive protection against the development of tumors in 
mice immunized with one dose of pgDe7e6e5 and depletion of CD4+ 
or CD8+ cells through inoculation of specific antibodies. The mice were 
challenged with 5x105 TC-1 tumor cells two weeks after administration 
of the vaccine.
 
Cytokines related to the activation or proliferation of cells of the immune 
system can be used as an alternative strategy to increase DnA vaccine-induced 
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response. Based on previous studies, we have developed a third version of DnA 
vaccines against HPV-16-induced tumors, which uses the co-administration of 
plasmids expressing the IL-12 or GM-CSf cytokines in combination with the 
plasmids expressing HPV-16 e7 or e7e6e5 genetically fused to HSV-1 gD. 
The use of this combined immunization system enabled achieving a maximum 
therapeutic protective effect, i.e., 100 percent tumor-free mice, with the co-
administration of the plasmid expressing IL-12 or GM-CSf and the plasmid 
expressing the target antigen (figure 2). Markedly, the increased antitumor ef-
fect of the vaccine enabled reducing the number of vaccine doses required for 
the complete elimination of the tumors, and with a single dose it was possible to 
confer therapeutic protection to all animals implanted with tumor cells.
figure 2 – Co-administration of pgDe7 vector and plasmids encoding IL-12 or GM-
CSf confers therapeutic protection to challenges of TC-1 cells. The mice 
were immunized with three doses (100 µg) of pgDe7 combined with 100 
µg of pcDnA3.1 (empty vector), PGM-CSf or pIL-12 vectors. The vac-
cines were administered 8 hours after challenge with 5 x 105 TC-1 cells. 
Tumor growth was monitored up to 60 days after challenge.
The evidence generated by these studies demonstrate that the proposed 
vaccine strategy is very promising as an immunologic alternative  for the con-
trol of HPV-16-induced tumors, with results better than those reported in the 
literature for other formulations tested in animal models. Additional studies are 
being carried out with the aim to test such vaccine formulations in clinical con-
ditions. for this purpose, additional modifications will be necessary to allow in-
creased immunogenicity in humans and decreased inflammatory reactions from 
the use of material obtained under good production conditions.
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Final considerations
Biotechnology has contributed decisively to the improvement of processes 
related to the development and production of new vaccines or to the improve-
ment of existing vaccines, for these to become safer and more effective. The avail-
ability of prophylactic anti-virus vaccines and the perspective for the development 
of vaccines with therapeutic effect on HPV-associated tumors clearly illustrate the 
impact of modern biotechnology on the field of vaccine research. epidemiological 
data released by the national Cancer Institute (InCA) show that in Brazil approx-
imately 20 out of each 100,000 women develop cervical cancer. A total of 20,000 
new cases are diagnosed each year, an incidence twice as high as that recorded in 
more developed countries. These data highlight the impact that vaccines directed 
to the control of HPV-associated tumors may have in the country.
The availability of prophylactic vaccines against infection with two HPV 
types has created great expectation towards a future reduction in the number 
of lives lost to the disease, as well as a decrease in the economic costs associated 
with the treatment of people with lesions in more advanced stages of this type of 
cancer. Reality, however, shows that the greatest impact of the vaccine formula-
tions introduced in the market has been of an economic nature for the pharma-
ceutical companies. The high cost of the vaccine (approximately $1,000.00 per 
person) has enabled manufacturers to earn profits exceeding $3 billion annually, 
a fact that has awaked the interest of many laboratories in investing in vaccines 
capable of yielding high financial returns. In turn, the real contribution of these 
vaccines to reduce the impact of the disease on the world is still unknown, since 
the people presently being capable to afford for them are less likely to feel the 
more serious consequences of the disease.
The development of a vaccine with therapeutic properties for the control 
of cancer associated with HPV infection would bring interesting perspectives in 
terms of real benefit of disease control. Unlike prophylactic anti-viral vaccines, 
therapeutic anti-tumor vaccines are expected to confer protection to a variety of 
HPV types and prevent the appearance of tumors in individuals already infected. 
The availability of this kind of treatment to the public health system, once the 
efficacy could be demonstrated in clinical trials, can have an immediate impact 
on the reduction of the number of deaths associated with the disease, and dra-
matically reduce the cost and traumas associated with the treatment of advanced 
cancer cases. However, as all research at an early stage of development, the al-
location of resources necessary to demonstrate clinical effects will be essential 
for these perspectives to materialize.
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abstraCt  – Vaccines represent the intervention strategy with the best cost-benefit  ra-
tio so far applied in public health. Biotechnological advances in various areas of vaccine 
research have contributed to the development of safer and more effective formulations. 
Moreover, application of biotechnology tools to vaccine development has caused chan-
ges in the way we think and produce these reagents for use in both humans and animals. 
Such technologies bring renewed perspectives that, in the near future, vaccines for the 
control of several non-preventable infectious and degenerative diseases will be available. 
In particular, the development of vaccines with therapeutic effects, although represen-
ting a huge challenge, are getting  closer to reality and will have a tremendous impact 
on the treatment of several diseases such as some cancer forms.
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